{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?q=B-cell+ALL", "query": { "q": "B-cell ALL" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10425, "total_pages": 1043, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?q=B-cell+ALL&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T06:49:09.144Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult", "Metastatic Breast Cancer", "Advanced Breast Cancer", "HER2 Mutation-Related Tumors", "HER2-positive Metastatic Breast Cancer", "KRAS Mutant Metastatic Colorectal Cancer", "Metastatic Lung Cancer", "Metastatic Colorectal Cancer", "Advanced Lung Cancer", "HR-positive, HER2-negative Advanced Breast Cancer", "HER2-positive Advanced Breast Cancer" ], "interventions": [ { "name": "BBO-10203", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 392, "start_date": "2024-10-29", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 19, "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06625775" }, { "nct_id": "NCT02224781", "title": "Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Melanoma", "Recurrent Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 267, "start_date": "2015-09-08", "completion_date": "2026-12-19", "has_results": true, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 839, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 529 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02224781" }, { "nct_id": "NCT04191187", "title": "Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Biphenotypic Acute Leukemia", "Undifferentiated Leukemia", "Prolymphocytic Leukemia", "Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia", "Myeloproliferative Neoplasm", "Relapsed Large Cell Lymphoma", "Mantle Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Relapsed T-Cell Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Relapsed Small Lymphocytic Lymphoma", "Relapsed Marginal B-cell Lymphoma", "Relapsed Follicular Lymphoma", "Lymphoplasmacytic Lymphoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2019-12-06", "completion_date": "2024-02-14", "has_results": true, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04191187" }, { "nct_id": "NCT03334487", "title": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Rovalpituzumab tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-03-15", "completion_date": "2018-12-20", "has_results": false, "last_update_posted_date": "2018-12-26", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 27, "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Fresno, California + 23 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334487" }, { "nct_id": "NCT06100237", "title": "Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Teclistamab", "type": "DRUG" }, { "name": "Talquetamab", "type": "DRUG" }, { "name": "Daratumumab SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carl Ola Landgren, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-12-04", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06100237" }, { "nct_id": "NCT05827081", "title": "Phase IIIb Study of Ribociclib + ET in Early Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Early Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ansastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1400, "start_date": "2024-02-28", "completion_date": "2030-09-20", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05827081" }, { "nct_id": "NCT02180867", "title": "Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alveolar Soft Part Sarcoma", "Angiomatoid Fibrous Histiocytoma", "Atypical Fibroxanthoma", "Clear Cell Sarcoma of Soft Tissue", "Epithelioid Malignant Peripheral Nerve Sheath Tumor", "Epithelioid Sarcoma", "Extraskeletal Myxoid Chondrosarcoma", "Extraskeletal Osteosarcoma", "Fibrohistiocytic Neoplasm", "Fibrosarcoma", "Inflammatory Myofibroblastic Tumor", "Intimal Sarcoma", "Leiomyosarcoma", "Liposarcoma", "Liver Embryonal Sarcoma", "Low Grade Fibromyxoid Sarcoma", "Low Grade Myofibroblastic Sarcoma", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Skin Granular Cell Tumor", "Malignant Triton Tumor", "Mesenchymal Chondrosarcoma", "Myxofibrosarcoma", "Myxoid Chondrosarcoma", "Myxoinflammatory Fibroblastic Sarcoma", "Nerve Sheath Neoplasm", "PEComa", "Pericytic Neoplasm", "Plexiform Fibrohistiocytic Tumor", "Sclerosing Epithelioid Fibrosarcoma", "Skin Glomus Tumor", "Stage IB Soft Tissue Sarcoma AJCC v7", "Stage IIB Soft Tissue Sarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Synovial Sarcoma", "Undifferentiated High Grade Pleomorphic Sarcoma of Bone" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 140, "start_date": "2014-08-12", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 365, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02180867" }, { "nct_id": "NCT00076063", "title": "A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ALVAC-HIV (vCP1452)", "type": "BIOLOGICAL" }, { "name": "LIPO-5", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 174, "start_date": "2004-03", "completion_date": "2007-03", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00076063" }, { "nct_id": "NCT00006237", "title": "S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "interleukin-2", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "interferon alfa", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 432, "start_date": "2000-08", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 296, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 197 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006237" }, { "nct_id": "NCT04549077", "title": "Pulmonary Vascular Disease in CF", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cystic Fibrosis" ], "interventions": [], "intervention_types": [], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "5 Years to 21 Years" }, "enrollment_count": 86, "start_date": "2020-07-29", "completion_date": "2026-01-01", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-07-24T06:49:09.144Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • Cincinnati, Ohio", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04549077" } ] }